The presence or absence of latent Epstein-Barr virus does not alter the sensitivity of Burkitt's lymphoma cell lines to proteasome inhibitors.
Cordova
Cory
C
Feist Weiller Cancer Center, Division of Hematology/Oncology, LSU Health Sciences Center, Shreveport, LA 71130, USA.
Munker
Reinhold
R
D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology*; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004854:Herpesvirus 4, Human / Q000378:metabolism*; D006801:Humans; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D017735:Virus Latency / Q000187:drug effects
D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D046988:Proteasome Endopeptidase Complex